Skip to main content

ThermoGenesis Announces Filing of 510 Application for MarrowXpress

Device Designed to Provide Point-of-Care Bone Marrow Processing

RANCHO CORDOVA, Calif., June 4, 2008 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. , a leading supplier of innovative products and services that process and store adult stem cells, today announced that it has submitted a 510(k) pre-market notification application to the FDA requesting regulatory clearance for its MarrowXpress(TM) (MXP(TM)), a device designed for the processing of bone marrow in a laboratory setting.

The device is a derivative of the Company's approved AutoXpress(TM) (AXP(TM)) Platform that is used to volume reduce and collect stem cells from umbilical cord blood.

"This is an important milestone in the Company's product diversification and growth strategy. We are hopeful that the regulatory process will be facilitated because the MXP is based on a currently approved device," said Dr. William Osgood, Chief Executive Officer.

Osgood said the Company expects to receive a CE Mark for the MXP this month, which would enable the Company to begin commercial marketing of the device in Europe.

"The use of adult stem cells to treat a variety of diseases and injuries is very promising. There are a number of clinical trials already underway, and in several countries it is a practice of medicine for indications such as critical limb ischemia, coronary artery disease and orthopedic conditions. We have had very encouraging discussions with leading research centers in both the U.S. and Europe regarding the potential use of the MXP in ongoing clinical trials and look forward to getting this device into the clinical setting. We believe this could ultimately represent a multi-billion dollar market opportunity for the Company," he added.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

    --  The BioArchive(R) System, an automated cryogenic device, is used by

        cord blood stem cell banks in more than 25 countries for

        cryopreserving and archiving cord blood stem cell units for

        transplant. GE Healthcare is the non-exclusive global distribution

        partner for the BioArchive System.

    --  AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of

        automated devices that includes the AXP and the MarrowXpress(TM) and

        companion sterile blood processing disposable for harvesting stem

        cells in a closed system. The AXP device is used for the processing of

        cord blood.  GE Healthcare is the exclusive global distribution

        partner for the AXP cord blood product.  The MarrowXpress is used for

        isolating stem cells from bone marrow.  ThermoGenesis sells the

        MarrowXpress directly to global customers.

    --  The CryoSeal(R) FS System, an automated device and companion sterile

        blood processing disposable, is used to prepare fibrin sealants from

        plasma in about an hour. We received FDA approval to market the

        CryoSeal FS System in liver resection surgeries in July 2007. The

        CryoSeal FS System has received the CE-Mark. From a marketing

        perspective, the CE Mark is the European equivalent to an FDA

        approval, in that it allows sales of the product throughout the

        European community. Asahi Medical is the exclusive distributor for the

        CryoSeal System in Japan and the Company markets through independent

        distributors in Europe and South America.

    --  The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood

        processing disposable that prepares activated thrombin from a small

        aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

        currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

        Biologics, Medtronic, Inc. and independent distributors.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

                             ThermoGenesis Corp.

                    Web site: http://www.thermogenesis.com

                         Contact: Investor Relations

                             +1-916-858-5107, or

                             ir@thermogenesis.com

CONTACT: Investor Relations of ThermoGenesis Corp., +1-916-858-5107, ir@thermogenesis.com

Web site: http://www.thermogenesis.com/

Ticker Symbol: (NASDAQ-NMS:KOOL)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2008

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.